Neuroscientific Biopharmaceuticals Ltd
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated … Read more
Neuroscientific Biopharmaceuticals Ltd (NSB) - Total Assets
Latest total assets as of June 2025: AU$16.96 Million AUD
Based on the latest financial reports, Neuroscientific Biopharmaceuticals Ltd (NSB) holds total assets worth AU$16.96 Million AUD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neuroscientific Biopharmaceuticals Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Neuroscientific Biopharmaceuticals Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neuroscientific Biopharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Neuroscientific Biopharmaceuticals Ltd's total assets of AU$16.96 Million consist of 43.6% current assets and 56.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$7.27 Million | 42.8% |
| Accounts Receivable | AU$98.36K | 0.6% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$870.00 | 0.0% |
| Intangible Assets | AU$9.57 Million | 56.4% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuroscientific Biopharmaceuticals Ltd's current assets represent 43.6% of total assets in 2025, a decrease from 75.7% in 2016.
- Cash Position: Cash and equivalents constituted 42.8% of total assets in 2025, up from 1.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 56.0% of total assets, an increase from 24.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 56.4% of total assets.
Neuroscientific Biopharmaceuticals Ltd Competitors by Total Assets
Key competitors of Neuroscientific Biopharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Neuroscientific Biopharmaceuticals Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Neuroscientific Biopharmaceuticals Ltd generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Neuroscientific Biopharmaceuticals Ltd is currently not profitable relative to its asset base.
Neuroscientific Biopharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 49.56 | 58.87 | 37.34 |
| Quick Ratio | 49.56 | 58.87 | 37.34 |
| Cash Ratio | 48.69 | 57.82 | 37.13 |
| Working Capital | AU$7.25 Million | AU$ 4.96 Million | AU$ 3.22 Million |
Neuroscientific Biopharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Neuroscientific Biopharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.57 |
| Latest Market Cap to Assets Ratio | 0.76 |
| Asset Growth Rate (YoY) | 212.1% |
| Total Assets | AU$16.96 Million |
| Market Capitalization | $12.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Neuroscientific Biopharmaceuticals Ltd's assets below their book value (0.76 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Neuroscientific Biopharmaceuticals Ltd's assets grew by 212.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuroscientific Biopharmaceuticals Ltd (2016–2025)
The table below shows the annual total assets of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$16.96 Million | +212.05% |
| 2024-06-30 | AU$5.44 Million | +2.74% |
| 2023-06-30 | AU$5.29 Million | -31.62% |
| 2022-06-30 | AU$7.74 Million | -47.82% |
| 2021-06-30 | AU$14.83 Million | +296.70% |
| 2020-06-30 | AU$3.74 Million | -27.05% |
| 2019-06-30 | AU$5.12 Million | +533.37% |
| 2018-06-30 | AU$808.90K | +39.72% |
| 2017-06-30 | AU$578.94K | +134.79% |
| 2016-06-30 | AU$246.58K | -- |